Hovione almost doubles spray drying capacity with multi-million euro investment in Cork
Hovione, an international pharmaceutical contract development and manufacturing organisation (CDMO), has officially commissioned an expansion at its manufacturing facility in Ringaskiddy, County Cork. The multi-million euro investment almost doubles the capacity of Hovione’s spray drying facilities in Ireland and will create more than 20 new positions.
This latest investment reinforces Hovione’s position as the global leader in spray drying for pharma applications. This manufacturing technology is especially important for inhalable therapies and oral medications with low bioavailability, enabling more effective treatments. By improving how medicines work in the body, spray drying plays a crucial role in delivering reliable, high-quality healthcare solutions that make a real difference in patients’ lives.
Jean-Luc Herbeaux, Hovione’s Chief Executive, said: “This newly opened facility further strengthens Hovione’s position as the global CDMO of choice for spray drying development and manufacturing services. It also underscores our commitment to bringing first-in-class technology and world-leading manufacturing services to Irish shores. Ireland provides a superior environment for pharmaceutical manufacturing, and we are delighted to be a part of it.”
Michael Lohan, CEO, IDA Ireland, said: “Since operations began here 15 years ago, Hovione has made a significant contribution both locally and nationally through employment and investment alike and I am pleased to be here to mark another step on that journey. We warmly welcome Hovione’s commitment to investing in Cork and we wish them continued success.”
This latest investment builds on the momentum of the recently announced spray drying capacity expansion at the company’s East Windsor, New Jersey, site. Hovione’s continuous commitment to enhance capacity and capabilities highlight its strategy to remain at the forefront of pharmaceutical technology. For over 65 years, Hovione has fostered a culture of innovation and operational excellence, consistently redefining what a CDMO can achieve. This dedication fuels Hovione’s mission to deliver world-class solutions to its pharmaceutical partners, enabling the launch and global supply of groundbreaking medicines that improve patients’ lives.
